{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:16:11Z","timestamp":1790698571827,"version":"4.1.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2021,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The ongoing SARS\u2010CoV\u20102 pandemic stresses the need for effective antiviral drugs that can quickly be applied in order to reduce morbidity, mortality, and ideally viral transmission. By repurposing of broadly active antiviral drugs and compounds that are known to inhibit viral replication of related viruses, several advances could be made in the development of treatment strategies against COVID\u201019. The nucleoside analog remdesivir, which is known for its potent\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity against Ebolavirus and other RNA viruses, was recently shown to reduce the time to recovery in patients with severe COVID\u201019. It is to date the only approved antiviral for treating COVID\u201019. Here, we provide a mechanism and evidence\u2010based comparative review of remdesivir and other repurposed drugs with proven\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity against SARS\u2010CoV\u20102.\n                  <\/jats:p>","DOI":"10.15252\/emmm.202013105","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T02:41:52Z","timestamp":1601865712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["A comparative analysis of remdesivir and other repurposed antivirals against SARS\u2010CoV\u20102"],"prefix":"10.1038","volume":"13","author":[{"given":"Alexander","family":"Simonis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian J","family":"Theobald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rybniker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2989-0436","authenticated-orcid":false,"given":"Jakob J","family":"Malin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"BFEMMM202013105_CR1","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","volume":"9","author":"ML Agostini","year":"2018","unstructured":"Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R et al (2018) Coronavirus susceptibility to the antiviral remdesivir (GS\u20105734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9: e00221\u2010e218","journal-title":"MBio"},{"key":"BFEMMM202013105_CR2","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.23.20110932","author":"PE Alexander","year":"2020","unstructured":"Alexander PE, Piticaru J, Lewis K, Aryal K, Thomas P, Szczeklik W, Fronczek J, Polok K, Alhazzani W, Mammen M (2020) Remdesivir use in patients with coronavirus COVID\u201019 disease: a systematic review and meta\u2010analysis. medRxiv https:\/\/doi.org\/10.1101\/2020.05.23.20110932 [PREPRINT]","journal-title":"medRxiv"},{"key":"BFEMMM202013105_CR3","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","volume":"300","author":"K Anand","year":"2003","unstructured":"Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R (2003) Coronavirus main proteinase (3CLpro) structure: basis for design of anti\u2010SARS drugs. Science 300: 1763\u20131767","journal-title":"Science"},{"key":"BFEMMM202013105_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-385504-6.00001-4","volume":"99","author":"TM Antalis","year":"2011","unstructured":"Antalis TM, Bugge TH, Wu Q (2011) Membrane\u2010anchored serine proteases in health and disease. Prog Mol Biol Transl Sci 99: 1\u201350","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"9","key":"BFEMMM202013105_CR5","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.3201\/eid2609.201495","volume":"26","author":"A Banerjee","year":"2020","unstructured":"Banerjee A, Nasir JA, Budylowski P, Yip L, Aftanas P, Christie N, Ghalami A, Baid K, Raphenya AR, Hirota JA et al (2020) Isolation, sequence, infectivity, and replication kinetics of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis 26(9): 2054\u20132063","journal-title":"Emerg Infect Dis"},{"key":"BFEMMM202013105_CR6","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, \u2026 Kline S et al (2020) Remdesivir for the treatment of covid\u201019 \u2010 preliminary report. N Engl J Med 383: 992\u2013993","journal-title":"N Engl J Med"},{"key":"BFEMMM202013105_CR7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","volume":"15","author":"YS Boriskin","year":"2008","unstructured":"Boriskin YS, Leneva IA, P\u00e9cheur EI, Polyak SJ (2008) Arbidol: a broad\u2010spectrum antiviral compound that blocks viral fusion. Curr Med Chem 15: 997\u20131005","journal-title":"Curr Med Chem"},{"key":"BFEMMM202013105_CR8","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1128\/JVI.77.16.8801-8811.2003","volume":"77","author":"BJ Bosch","year":"2003","unstructured":"Bosch BJ, van der Zee R, de Haan CA, Rottier PJ (2003) The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 77: 8801\u20138811","journal-title":"J Virol"},{"key":"BFEMMM202013105_CR9","doi-asserted-by":"crossref","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","volume":"169","author":"AJ Brown","year":"2019","unstructured":"Brown AJ, Won JJ, Graham RL, Dinnon KH, Sims AC, Feng JY, Cihlar T, Denison MR, Baric RS, Sheahan TP (2019) Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res 169: 104541","journal-title":"Antiviral Res"},{"key":"BFEMMM202013105_CR10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004502","volume":"10","author":"C Burkard","year":"2014","unstructured":"Burkard C, Verheije MH, Wicht O, van Kasteren SI, van Kuppeveld FJ, Haagmans BL, Pelkmans L, Rottier PJM, Bosch BJ, de Haan CAM (2014) Coronavirus cell entry occurs through the endo\u2010\/lysosomal pathway in a proteolysis\u2010dependent manner. PLoS Pathog 10: e1004502","journal-title":"PLoS Pathog"},{"key":"BFEMMM202013105_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.007","author":"Q Cai","year":"2020","unstructured":"Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y et al (2020) Experimental treatment with favipiravir for COVID\u201019: an open\u2010label control study. Engineering (Beijing). https:\/\/doi.org\/10.1016\/j.eng.2020.03.007","journal-title":"Engineering (Beijing)"},{"key":"BFEMMM202013105_CR12","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M et al (2020) A trial of lopinavir\u2010ritonavir in adults hospitalized with severe Covid\u201019. N Engl J Med 382: 1787\u20131799","journal-title":"N Engl J Med"},{"key":"BFEMMM202013105_CR13","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","volume":"212","author":"JF\u2010W Chan","year":"2015","unstructured":"Chan JF\u2010W, Yao Y, Yeung M\u2010L, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P et al (2015) Treatment with Lopinavir\/Ritonavir or interferon\u2010\u03b21b improves outcome of MERS\u2010CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212: 1904\u20131913","journal-title":"J Infect Dis"},{"key":"BFEMMM202013105_CR14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5009\/gnl.2009.3.3.205","volume":"3","author":"JH Chang","year":"2009","unstructured":"Chang JH, Lee IS, Kim HK, Cho YK, Park JM, Kim SW, Choi M\u2010G, Chung IS (2009) Nafamostat for Prophylaxis against Post\u2010Endoscopic Retrograde Cholangiopancreatography Pancreatitis Compared with Gabexate. Gut Liv 3: 205\u2013210","journal-title":"Gut Liv"},{"key":"BFEMMM202013105_CR15","first-page":"215","volume":"49","author":"J Chen","year":"2020","unstructured":"Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, Ling Y, Huang D, Song S, Zhang D et al (2020a) A pilot study of hydroxychloroquine in treatment of patients with moderate COVID\u201019. Zhejiang Da Xue Xue Bao Yi Xue Ban 49: 215\u2013219","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"BFEMMM202013105_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.22.20040758","author":"Z Chen","year":"2020","unstructured":"Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, Zhuang R, Hu B, Zhang Z (2020b) Efficacy of hydroxychloroquine in patients with COVID\u201019: results of a randomized clinical trial. medRxiv https:\/\/doi.org\/10.1101\/2020.03.22.20040758 [PREPRINT]","journal-title":"medRxiv"},{"key":"BFEMMM202013105_CR17","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.bmcl.2012.02.105","volume":"22","author":"A Cho","year":"2012","unstructured":"Cho A, Saunders OL, Butler T, Zhang L, Xu J, Vela JE, Feng JY, Ray AS, Kim CU (2012) Synthesis and antiviral activity of a series of 1'\u2010substituted 4\u2010aza\u20107,9\u2010dideazaadenosine C\u2010nucleosides. Bioorg Med Chem Lett 22: 2705\u20132707","journal-title":"Bioorg Med Chem Lett"},{"key":"BFEMMM202013105_CR18","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","volume":"178","author":"KT Choy","year":"2020","unstructured":"Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PP, Huang X et al (2020) Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS\u2010CoV\u20102 replication in vitro. Antiviral Res 178: 104786","journal-title":"Antiviral Res"},{"key":"BFEMMM202013105_CR19","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/S0140-6736(03)13615-X","volume":"361","author":"J Cinatl","year":"2003","unstructured":"Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW (2003) Glycyrrhizin, an active component of liquorice roots, and replication of SARS\u2010associated coronavirus. Lancet 361: 2045\u20132046","journal-title":"Lancet"},{"key":"BFEMMM202013105_CR20","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3389\/fimmu.2020.01439","volume":"11","author":"S Colafrancesco","year":"2020","unstructured":"Colafrancesco S, Scrivo R, Barbati C, Conti F, Priori R (2020) Targeting the immune system for pulmonary inflammation and cardiovascular complications in COVID\u201019 patients. Front Immunol 11: 1439","journal-title":"Front Immunol"},{"key":"BFEMMM202013105_CR21","first-page":"20285","volume":"17","author":"VM Corman","year":"2012","unstructured":"Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach\u2010Bludau M, van Boheemen S, Gopal R, Ballhause M, Bestebroer TM et al (2012) Detection of a novel human coronavirus by real\u2010time reverse\u2010transcription polymerase chain reaction. Euro Surveill 17: 20285","journal-title":"Euro Surveill"},{"key":"BFEMMM202013105_CR22","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.17.20133579","author":"L Corral","year":"2020","unstructured":"Corral L, Bahamonde A, Arnaiz delas Revillas F, Gomez\u2010Barquero J, Abadia\u2010Otero J, Garcia\u2010Ibarbia C, Mora V, Cerezo\u2010Hernandez A, Hernandez JL, Lopez\u2010Muniz G et al (2020) GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID\u201019 pneumonia. medRxiv https:\/\/doi.org\/10.1101\/2020.06.17.20133579 [PREPRINT]","journal-title":"medRxiv"},{"key":"BFEMMM202013105_CR23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0166-3542(02)00185-7","volume":"58","author":"JM Crance","year":"2003","unstructured":"Crance JM, Scaramozzino N, Jouan A, Garin D (2003) Interferon, ribavirin, 6\u2010azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 58: 73\u201379","journal-title":"Antiviral Res"},{"key":"BFEMMM202013105_CR24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0065-3527(05)64006-7","volume":"64","author":"CA de Haan","year":"2005","unstructured":"de Haan CA, Rottier PJ (2005) Molecular interactions in the assembly of coronaviruses. Adv Virus Res 64: 165\u2013230","journal-title":"Adv Virus Res"},{"key":"BFEMMM202013105_CR25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijid.2020.05.085","volume":"97","author":"S De Meyer","year":"2020","unstructured":"De Meyer S, Bojkova D, Cinatl J, Van Damme E, Buyck C, Van Loock M, Woodfall B, Ciesek S (2020) Lack of antiviral activity of darunavir against SARS\u2010CoV\u20102. Int J Infect Dis 97: 7\u201310","journal-title":"Int J Infect Dis"},{"key":"BFEMMM202013105_CR26","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","volume":"58","author":"AH de Wilde","year":"2014","unstructured":"de Wilde AH, Jochmans D, Posthuma CC, ZevenhoVen\u2010Dobbe JC, van Nieuwkoop S, Bestebroer TM, van Den Hoogen BG, Neyts J, Snijder EJ (2014) Screening of an FDA\u2010approved compound library identifies four small\u2010molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58: 4875\u20134884","journal-title":"Antimicrob Agents Chemother"},{"key":"BFEMMM202013105_CR27","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1099\/vir.0.034983-0","volume":"92","author":"AH de Wilde","year":"2011","unstructured":"de Wilde AH, Zevenhoven\u2010Dobbe JC, van der Meer Y, Thiel V, Narayanan K, Makino S, Snijder EJ, van Hemert MJ (2011) Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol 92: 2542\u20132548","journal-title":"J Gen Virol"},{"key":"BFEMMM202013105_CR28","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","volume":"117","author":"E de Wit","year":"2020","unstructured":"de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H (2020) Prophylactic and therapeutic remdesivir (GS\u20105734) treatment in the rhesus macaque model of MERS\u2010CoV infection. Proc Natl Acad Sci USA 117: 6771\u20136776","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM202013105_CR29","doi-asserted-by":"publisher","DOI":"10.31219\/osf.io\/urxwh","author":"SK Dey","year":"2020","unstructured":"Dey SK, Saini M, Dhembla C, Bhatt S, Rajesh AS, Anand V, Kundu S (2020) Suramin, Penciclovir and Anidulafungin bind nsp12, which governs the RNA\u2010dependent\u2010RNA polymerase activity of SARS\u2010CoV\u20102, with higher interaction energy than Remdesivir, indicating potential in the treatment of Covid\u201019 infection. OSF Preprints https:\/\/doi.org\/10.31219\/osf.io\/urxwh [PREPRINT]","journal-title":"OSF Preprints"},{"key":"BFEMMM202013105_CR30","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","volume":"348","author":"C Drosten","year":"2003","unstructured":"Drosten C, G\u00fcnther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA et al (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967\u20131976","journal-title":"N Engl J Med"},{"key":"BFEMMM202013105_CR31","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.cgh.2020.04.002","volume":"18","author":"Z Fan","year":"2020","unstructured":"Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J (2020) Clinical features of COVID\u201019\u2010related liver functional abnormality. Clin Gastroenterol Hepatol 18: 1561\u20131566","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFEMMM202013105_CR32","volume-title":"Fact Sheet For Health Care Providers Emergency Use Authorization (Eua) Of Veklury\u00ae (remdesivir)","author":"Food and Drug Administration (FDA)","year":"2020","unstructured":"Food and Drug Administration (FDA) (2020) Fact Sheet For Health Care Providers Emergency Use Authorization (Eua) Of Veklury\u00ae (remdesivir), Available at: www.fda.gov\/media\/137566\/download Accessed 12.08.2020"},{"key":"BFEMMM202013105_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","volume":"1282","author":"AR Fehr","year":"2015","unstructured":"Fehr AR, Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 1282: 1\u201323","journal-title":"Methods Mol Biol"},{"key":"BFEMMM202013105_CR34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (2013) Favipiravir (T\u2010705), a novel viral RNA polymerase inhibitor. Antiviral Res 100: 446\u2013454","journal-title":"Antiviral Res"},{"key":"BFEMMM202013105_CR35","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","volume":"46","author":"Y Furuta","year":"2002","unstructured":"Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y et al (2002) In vitro and in vivo activities of anti\u2010influenza virus compound T\u2010705. Antimicrob Agents Chemother 46: 977\u2013981","journal-title":"Antimicrob Agents Chemother"},{"key":"BFEMMM202013105_CR36","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1128\/jvi.65.4.1916-1928.1991","volume":"65","author":"TM Gallagher","year":"1991","unstructured":"Gallagher TM, Escarmis C, Buchmeier MJ (1991) Alteration of the pH dependence of coronavirus\u2010induced cell fusion: effect of mutations in the spike glycoprotein. J Virol 65: 1916\u20131928","journal-title":"J Virol"},{"key":"BFEMMM202013105_CR37","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/1078-0432.CCR-13-1283","volume":"20","author":"V Gandhi","year":"2014","unstructured":"Gandhi V, Plunkett W, Cortes JE (2014) Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res 20: 1735\u20131740","journal-title":"Clin Cancer Res"},{"key":"BFEMMM202013105_CR38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao J, Tian Z, Yang X (2020) Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID\u201019 associated pneumonia in clinical studies. Biosci Trends 14: 72\u201373","journal-title":"Biosci Trends"},{"key":"BFEMMM202013105_CR39","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID\u201019: results of an open\u2010label non\u2010randomized clinical trial. Int J Antimicrob Agents 105949","DOI":"10.1101\/2020.03.16.20037135"},{"key":"BFEMMM202013105_CR40","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","volume":"382","author":"J Geleris","year":"2020","unstructured":"Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson DK, Kubin C, Barr RG et al (2020) Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid\u201019. N Engl J Med 382: 2411\u20132418","journal-title":"N Engl J Med"},{"key":"BFEMMM202013105_CR41","first-page":"115","volume-title":"Remdesivir (GS\u20105734\u00ae) Investigator's Brochure Version 5.0","author":"Gilead Sciences","year":"2020","unstructured":"Gilead Sciences (2020) Remdesivir (GS\u20105734\u00ae) Investigator's Brochure Version 5.0. Foster City, CA, Gilead Sciences, Inc., 115\u2013116."},{"key":"BFEMMM202013105_CR42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2015301","author":"JD Goldman","year":"2020","unstructured":"Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG et al (2020) Remdesivir for 5 or 10 days in patients with severe Covid\u201019. N Engl J Med https:\/\/doi.org\/10.1056\/NEJMoa2015301.","journal-title":"N Engl J Med"},{"key":"BFEMMM202013105_CR43","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","volume":"295","author":"CJ Gordon","year":"2020","unstructured":"Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, G\u00f6tte M (2020a) The antiviral compound remdesivir potently inhibits RNA\u2010dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 295: 4773\u20134779","journal-title":"J Biol Chem"},{"key":"BFEMMM202013105_CR44","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","volume":"295","author":"CJ Gordon","year":"2020","unstructured":"Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, G\u00f6tte M (2020b) Remdesivir is a direct\u2010acting antiviral that inhibits RNA\u2010dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 295: 6785\u20136797","journal-title":"J Biol Chem"},{"issue":"24","key":"BFEMMM202013105_CR45","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","volume":"382","author":"J Grein","year":"2020","unstructured":"Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX et al (2020) Compassionate use of remdesivir for patients with severe Covid\u201019. N Engl J Med. 382(24): 2327\u20132336","journal-title":"N Engl J Med"},{"key":"BFEMMM202013105_CR46","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.1087139","volume":"302","author":"Y Guan","year":"2003","unstructured":"Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ et al (2003) Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China. Science 302: 276\u2013278","journal-title":"Science"},{"key":"BFEMMM202013105_CR47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0092-8674(77)90140-4","volume":"10","author":"RS Gupta","year":"1977","unstructured":"Gupta RS, Siminovitch L (1977) The molecular basis of emetine resistance in Chinese hamster ovary cells: alteration in the 40S ribosomal subunit. Cell 10: 61\u201366","journal-title":"Cell"},{"issue":"2","key":"BFEMMM202013105_CR48","doi-asserted-by":"crossref","first-page":"106055","DOI":"10.1016\/j.ijantimicag.2020.106055","volume":"56","author":"J He","year":"2020","unstructured":"He J, Hu L, Huang X, Wang C, Zhang Z, Wang Y, Zhang D, Ye W (2020a) Potential of coronavirus 3C\u2010like protease inhibitors for the development of new anti\u2010SARS\u2010CoV\u20102 drugs: Insights from structures of protease and inhibitors. Int J Antimicrob Agents 56(2): 106055","journal-title":"Int J Antimicrob Agents"},{"key":"BFEMMM202013105_CR49","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","volume":"26","author":"X He","year":"2020","unstructured":"He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X et al (2020b) Temporal dynamics in viral shedding and transmissibility of COVID\u201019. Nat Med 26: 672\u2013675","journal-title":"Nat Med"},{"key":"BFEMMM202013105_CR50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine\u2010Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A et al (2020a) SARS\u2010CoV\u20102 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181: 271\u2013280.","journal-title":"Cell"},{"key":"BFEMMM202013105_CR5100","doi-asserted-by":"crossref","first-page":"e00754","DOI":"10.1128\/AAC.00754-20","volume":"64","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Schroeder S, Kleine\u2010Weber H, M\u00fcller MA, Drosten C, P\u00f6hlmann S (2020b) Nafamostat mesylate blocks activation of SARS\u2010CoV\u20102: new treatment option for COVID\u201019. Antimicrob Agents Chemother 64: e00754\u201020","journal-title":"Antimicrob Agents Chemother"},{"key":"BFEMMM202013105_CR51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","author":"P Horby","year":"2020","unstructured":"Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E et al (2020) Dexamethasone in hospitalized patients with Covid\u201019 \u2013 preliminary report. N Engl J Med https:\/\/doi.org\/10.1056\/NEJMoa2021436","journal-title":"N Engl J Med"},{"key":"BFEMMM202013105_CR52","first-page":"E734","volume":"192","author":"D Huang","year":"2020","unstructured":"Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z (2020) Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID\u201019): A systematic review and meta\u2010analysis. J Med Virol 192: E734\u2013E744","journal-title":"J Med Virol"},{"key":"BFEMMM202013105_CR53","volume":"93","author":"N Iwata\u2010Yoshikawa","year":"2019","unstructured":"Iwata\u2010Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M, Nagata N (2019) TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol 93: e01815\u201018","journal-title":"J Virol"},{"key":"BFEMMM202013105_CR54","first-page":"Cd008965","volume":"2014","author":"T Jefferson","year":"2014","unstructured":"Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D et al (2014) Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014: Cd008965","journal-title":"Cochrane Database Syst Rev"},{"key":"BFEMMM202013105_CR55","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1128\/AAC.00709-16","volume":"60","author":"D Jochmans","year":"2016","unstructured":"Jochmans D, van Nieuwkoop S, Smits SL, Neyts J, Fouchier RA, van den Hoogen BG (2016) Antiviral activity of favipiravir (T\u2010705) against a broad range of paramyxoviruses in vitro and against human metapneumovirus in hamsters. Antimicrob Agents Chemother 60: 4620\u20134629","journal-title":"Antimicrob Agents Chemother"},{"key":"BFEMMM202013105_CR56","unstructured":"Johns Hopkins University (JHU) (2020). COVID\u201019 Dashboard by the Center for Systems Science and Engineering (CSSE). Available at: http:\/\/isanddata.maps.arcgis.com\/apps\/opsdashboard\/index.html#\/bda7594740fd40299423467b48e9ecf6. Accessed September, 22 2020"},{"key":"BFEMMM202013105_CR57","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","volume":"12","author":"LP Jordheim","year":"2013","unstructured":"Jordheim LP, Durantel D, Zoulim F, Dumontet C (2013) Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov 12: 447\u2013464","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM202013105_CR58","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/pathogens9070546","volume":"9","author":"RS Kalra","year":"2020","unstructured":"Kalra RS, Tomar D, Meena AS, Kandimalla R (2020) SARS\u2010CoV\u20102, ACE2, and hydroxychloroquine: cardiovascular complications, therapeutics, and clinical readouts in the current settings. Pathogens 9: 546","journal-title":"Pathogens"},{"key":"BFEMMM202013105_CR59","volume":"9","author":"TJ Kamp","year":"2020","unstructured":"Kamp TJ, Hamdan MH, January CT (2020) Chloroquine or hydroxychloroquine for COVID\u201019: is cardiotoxicity a concern? J Am Heart Assoc 9: e016887","journal-title":"J Am Heart Assoc"},{"key":"BFEMMM202013105_CR60","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/JVI.00094-12","volume":"86","author":"M Kawase","year":"2012","unstructured":"Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S (2012) Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol 86: 6537\u20136545","journal-title":"J Virol"},{"key":"BFEMMM202013105_CR61","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","volume":"323","author":"E Keyaerts","year":"2004","unstructured":"Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M (2004) In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Comm 323: 264\u2013268","journal-title":"Biochem Biophys Res Comm"},{"key":"BFEMMM202013105_CR62","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","volume":"348","author":"TG Ksiazek","year":"2003","unstructured":"Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W et al (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348: 1953\u20131966","journal-title":"N Engl J Med"},{"key":"BFEMMM202013105_CR63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/03009747409115809","volume":"3","author":"AL Laaksonen","year":"1974","unstructured":"Laaksonen AL, Koskiahde V, Juva K (1974) Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand J Rheumatol 3: 103\u2013108","journal-title":"Scand J Rheumatol"},{"key":"BFEMMM202013105_CR64","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.31301","volume":"72","author":"F Lei","year":"2020","unstructured":"Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, \u2026 Ouyang S et al (2020) Longitudinal association between markers of liver injury and mortality in COVID\u201019 in China. Hepatology 72: 389\u2013398","journal-title":"Hepatology"},{"key":"BFEMMM202013105_CR65","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2008.10.009","volume":"81","author":"IA Leneva","year":"2009","unstructured":"Leneva IA, Russell RJ, Boriskin YS, Hay AJ (2009) Characteristics of arbidol\u2010resistant mutants of influenza virus: implications for the mechanism of anti\u2010influenza action of arbidol. Antiviral Res 81: 132\u2013140","journal-title":"Antiviral Res"},{"key":"BFEMMM202013105_CR66","doi-asserted-by":"crossref","first-page":"m1335","DOI":"10.1136\/bmj.m1335","volume":"369","author":"J Lenzer","year":"2020","unstructured":"Lenzer J (2020) Covid\u201019: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ 369: m1335","journal-title":"BMJ"},{"key":"BFEMMM202013105_CR67","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC et al (2003) Angiotensin\u2010converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426: 450\u2013454","journal-title":"Nature"},{"key":"BFEMMM202013105_CR68","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1126\/science.1118391","volume":"310","author":"W Li","year":"2005","unstructured":"Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H et al (2005) Bats are natural reservoirs of SARS\u2010like coronaviruses. Science 310: 676\u2013679","journal-title":"Science"},{"key":"BFEMMM202013105_CR69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, \u2026 Wang M (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS\u2010CoV\u20102 infection in vitro. Cell Discov 6: 16","journal-title":"Cell Discov"},{"key":"BFEMMM202013105_CR70","doi-asserted-by":"crossref","first-page":"43395","DOI":"10.1038\/srep43395","volume":"7","author":"MK Lo","year":"2017","unstructured":"Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava\u2010Ranjan P, Hotard AL, Flint M, McMullan LK, Siegel D, Clarke MO et al (2017) GS\u20105734 and its parent nucleoside analog inhibit Filo\u2010, Pneumo\u2010, and Paramyxoviruses. Sci Rep 7: 43395","journal-title":"Sci Rep"},{"key":"BFEMMM202013105_CR71","doi-asserted-by":"crossref","first-page":"m1844","DOI":"10.1136\/bmj.m1844","volume":"369","author":"M Mah\u00e9vas","year":"2020","unstructured":"Mah\u00e9vas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, Fois E, Lepeule R, Szwebel TA, Lescure FX et al (2020) Clinical efficacy of hydroxychloroquine in patients with covid\u201019 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 369: m1844","journal-title":"BMJ"},{"key":"BFEMMM202013105_CR72","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41586-020-2558-4","volume":"585","author":"P Maisonnasse","year":"2020","unstructured":"Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, Marlin R, Naninck T, Pizzorno A, Lemaitre J, Gon\u00e7alves A et al (2020) Hydroxychloroquine use against SARS\u2010CoV\u20102 infection in non\u2010human primates. Nature 585: 584\u2013587","journal-title":"Nature"},{"key":"BFEMMM202013105_CR73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","volume":"75","author":"EW McChesney","year":"1983","unstructured":"McChesney EW (1983) Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med 75: 11\u201318","journal-title":"Am J Med"},{"key":"BFEMMM202013105_CR74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12985-016-0544-0","volume":"13","author":"HA Mohd","year":"2016","unstructured":"Mohd HA, Al\u2010Tawfiq JA, Memish ZA (2016) Middle east respiratory syndrome coronavirus (MERS\u2010CoV) origin and animal reservoir. Virol J 13: 87","journal-title":"Virol J"},{"key":"BFEMMM202013105_CR75","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu S, Dodd LE, Davey Jr RT, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A et al (2019) A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med 381: 2293\u20132303","journal-title":"N Engl J Med"},{"key":"BFEMMM202013105_CR76","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.01184-07","volume":"52","author":"E Murakami","year":"2008","unstructured":"Murakami E, Niu C, Bao H, Micolochick Steuer HM, Whitaker T, Nachman T, Sofia MA, Wang P, Otto MJ, Furman PA (2008) The mechanism of action of beta\u2010D\u20102'\u2010deoxy\u20102'\u2010fluoro\u20102'\u2010C\u2010methylcytidine involves a second metabolic pathway leading to beta\u2010D\u20102'\u2010deoxy\u20102'\u2010fluoro\u20102'\u2010C\u2010methyluridine 5'\u2010triphosphate, a potent inhibitor of the hepatitis C virus RNA\u2010dependent RNA polymerase. Antimicrob Agents Chemother 52: 458\u2013464","journal-title":"Antimicrob Agents Chemother"},{"key":"BFEMMM202013105_CR77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-4690-4-6","volume":"4","author":"MA Naarding","year":"2007","unstructured":"Naarding MA, Baan E, Pollakis G, Paxton WA (2007) Effect of chloroquine on reducing HIV\u20101 replication in vitro and the DC\u2010SIGN mediated transfer of virus to CD4+ T\u2010lymphocytes. Retrovirology 4: 6","journal-title":"Retrovirology"},{"key":"BFEMMM202013105_CR78","unstructured":"National Institutes of Health (NIH) (2020). NIH halts clinical trial of hydroxychloroquine. Press release available at: www.nih.gov\/news\u2010events\/news\u2010releases\/nih\u2010halts\u2010clinical\u2010trial\u2010hydroxychloroquine. Accessed June, 28 2020"},{"key":"BFEMMM202013105_CR79","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0163-7258(97)00084-3","volume":"77","author":"PM O'Neill","year":"1998","unstructured":"O'Neill PM, Bray PG, Hawley SR, Ward SA, Park BK (1998) 4\u2010Aminoquinolines\u2013past, present, and future: a chemical perspective. Pharmacol Ther 77: 29\u201358","journal-title":"Pharmacol Ther"},{"key":"BFEMMM202013105_CR80","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1099\/jgv.0.001453","volume":"101","author":"NS Ogando","year":"2020","unstructured":"Ogando NS, Dalebout TJ, Zevenhoven\u2010Dobbe JC, Limpens RWAL, van der Meer Y, Caly L, Druce J, de Vries JJC, Kikkert M, B\u00e1rcena M et al (2020) SARS\u2010coronavirus\u20102 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology. J Gen Virol. 101: 925\u2013940","journal-title":"J Gen Virol"},{"key":"BFEMMM202013105_CR81","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","volume":"11","author":"X Ou","year":"2020","unstructured":"Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J et al (2020) Characterization of spike glycoprotein of SARS\u2010CoV\u20102 on virus entry and its immune cross\u2010reactivity with SARS\u2010CoV. Nat Commun 11: 1620","journal-title":"Nat Commun"},{"key":"BFEMMM202013105_CR82","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s12291-020-00900-x","volume":"35","author":"A Pal","year":"2020","unstructured":"Pal A, Pawar A, Goswami K, Sharma P, Prasad R (2020) Hydroxychloroquine and Covid\u201019: a cellular and molecular biology based update. Indian J Clin Biochem 35: 274\u2013284","journal-title":"Indian J Clin Biochem"},{"key":"BFEMMM202013105_CR83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1468-1293.2005.00259.x","volume":"6","author":"NI Paton","year":"2005","unstructured":"Paton NI, Aboulhab J (2005) Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV\u2010infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med 6: 13\u201320","journal-title":"HIV Med"},{"key":"BFEMMM202013105_CR84","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S0140-6736(02)08557-4","volume":"359","author":"NI Paton","year":"2002","unstructured":"Paton NI, Aboulhab J, Karim F (2002) Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV\u20101. Lancet 359: 1667\u20131668","journal-title":"Lancet"},{"key":"BFEMMM202013105_CR85","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(03)13077-2","volume":"361","author":"JS Peiris","year":"2003","unstructured":"Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT et al (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361: 1319\u20131325","journal-title":"Lancet"},{"key":"BFEMMM202013105_CR86","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3851\/IMP2012","volume":"22","author":"F Pertusati","year":"2012","unstructured":"Pertusati F, Serpi M, McGuigan C (2012) Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy. Antivir Chem Chemother 22: 181\u2013203","journal-title":"Antivir Chem Chemother"},{"key":"BFEMMM202013105_CR87","doi-asserted-by":"crossref","first-page":"104878","DOI":"10.1016\/j.antiviral.2020.104878","volume":"181","author":"A Pizzorno","year":"2020","unstructured":"Pizzorno A, Padey B, Dubois J, Julien T, Traversier A, Duli\u00e8re V, Brun P, Lina B, Rosa\u2010Calatrava M, Terrier O (2020) In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS\u2010CoV\u20102. Antiviral Res 181: 104878","journal-title":"Antiviral Res"},{"key":"BFEMMM202013105_CR88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/rheumatology\/15.3.235","volume":"15","author":"AJ Popert","year":"1976","unstructured":"Popert AJ (1976) Chloroquine: a review. Rheumatol Rehabil 15: 235\u2013238","journal-title":"Rheumatol Rehabil"},{"key":"BFEMMM202013105_CR89","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2020-218479","volume":"79","author":"S Ramiro","year":"2020","unstructured":"Ramiro S, Mostard RLM, Magro\u2010Checa C, van Dongen CMP, Dormans T, Buijs J, Gronenschild M, de Kruif MD, van Haren EHJ, van Kraaij T et al (2020) Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID\u201019\u2010associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis 79: 1143\u20131151","journal-title":"Ann Rheum Dis"},{"key":"BFEMMM202013105_CR90","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s13063-019-3606-y","volume":"20","author":"ML Ramsey","year":"2019","unstructured":"Ramsey ML, Nuttall J, Hart PA (2019) A phase 1\/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI\u201003 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC). Trials 20: 501","journal-title":"Trials"},{"key":"BFEMMM202013105_CR91","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0042-6822(90)90099-D","volume":"174","author":"VB Randolph","year":"1990","unstructured":"Randolph VB, Winkler G, Stollar V (1990) Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 174: 450\u2013458","journal-title":"Virology"},{"issue":"Suppl 1","key":"BFEMMM202013105_CR92","first-page":"102","volume":"5","author":"JC Rau","year":"2007","unstructured":"Rau JC, Beaulieu LM, Huntington JA, Church FC (2007) Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 5(Suppl 1): 102\u2013115","journal-title":"J Thromb Haemost"},{"key":"BFEMMM202013105_CR93","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","volume":"30","author":"JM Rolain","year":"2007","unstructured":"Rolain JM, Colson P, Raoult D (2007) Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30: 297\u2013308","journal-title":"Int J Antimicrob Agents"},{"key":"BFEMMM202013105_CR94","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1128\/AAC.00649-13","volume":"57","author":"H Sangawa","year":"2013","unstructured":"Sangawa H, Komeno T, Nishikawa H, Yoshida A, Takahashi K, Nomura N, Furuta Y (2013) Mechanism of action of T\u2010705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57: 5202\u20135208","journal-title":"Antimicrob Agents Chemother"},{"key":"BFEMMM202013105_CR95","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00126334-200403010-00002","volume":"35","author":"A Savarino","year":"2004","unstructured":"Savarino A, Lucia MB, Rastrelli E, Rutella S, Golotta C, Morra E, Tamburrini E, Perno CF, Boelaert JR, Sperber K et al (2004) Anti\u2010HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 35: 223\u2013232","journal-title":"J Acquir Immune Defic Syndr"},{"key":"BFEMMM202013105_CR96","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16: 155\u2013166","journal-title":"Nat Rev Rheumatol"},{"key":"BFEMMM202013105_CR97","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.antiviral.2018.04.004","volume":"154","author":"KL Seley\u2010Radtke","year":"2018","unstructured":"Seley\u2010Radtke KL, Yates MK (2018) The evolution of nucleoside analogue antivirals: A review for chemists and non\u2010chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antiviral Res 154: 66\u201386","journal-title":"Antiviral Res"},{"key":"BFEMMM202013105_CR98","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","volume":"42","author":"HL Sham","year":"1998","unstructured":"Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A et al (1998) ABT\u2010378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 42: 3218\u20133224","journal-title":"Antimicrob Agents Chemother"},{"key":"BFEMMM202013105_CR99","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.15.098731","author":"A Shannon","year":"2020","unstructured":"Shannon A, Selisko B, Le N, Huchting J, Touret F, Piorkowski G, Fattorini V, Ferron F, Decroly E, Meier C et al (2020) Favipiravir strikes the SARS\u2010CoV\u20102 at its Achilles heel, the RNA polymerase. bioRxiv https:\/\/doi.org\/10.1101\/2020.05.15.098731 [PREPRINT]","journal-title":"bioRxiv"},{"key":"BFEMMM202013105_CR100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.micinf.2020.04.004","volume":"22","author":"A Sharma","year":"2020","unstructured":"Sharma A (2020) Chloroquine paradox may cause more damage than help fight COVID\u201019. Microbes Infect 22: 154\u2013156","journal-title":"Microbes Infect"},{"key":"BFEMMM202013105_CR101","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I et al (2017) Broad\u2010spectrum antiviral GS\u20105734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9: eaal3653","journal-title":"Sci Transl Med"},{"key":"BFEMMM202013105_CR102","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO et al (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS\u2010CoV. Nat Commun 11: 222","journal-title":"Nat Commun"},{"key":"BFEMMM202013105_CR103","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virol.2017.11.012","volume":"517","author":"K Shirato","year":"2018","unstructured":"Shirato K, Kawase M, Matsuyama S (2018) Wild\u2010type human coronaviruses prefer cell\u2010surface TMPRSS2 to endosomal cathepsins for cell entry. Virology 517: 9\u201315","journal-title":"Virology"},{"key":"BFEMMM202013105_CR104","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1099\/0022-1317-83-7-1535","volume":"83","author":"SB Sieczkarski","year":"2002","unstructured":"Sieczkarski SB, Whittaker GR (2002) Dissecting virus entry via endocytosis. J Gen Virol 83: 1535\u20131545","journal-title":"J Gen Virol"},{"key":"BFEMMM202013105_CR105","doi-asserted-by":"crossref","first-page":"104759","DOI":"10.1016\/j.antiviral.2020.104759","volume":"177","author":"CJ Sigrist","year":"2020","unstructured":"Sigrist CJ, Bridge A, Le Mercier P (2020) A potential role for integrins in host cell entry by SARS\u2010CoV\u20102. Antiviral Res 177: 104759","journal-title":"Antiviral Res"},{"key":"BFEMMM202013105_CR106","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, Arribas L\u00f3pez JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A et al (2020) Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID\u201019: a randomized clinical trial. JAMA 324: 1048","journal-title":"JAMA"},{"key":"BFEMMM202013105_CR107","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1073\/pnas.70.4.1174","volume":"70","author":"DG Streeter","year":"1973","unstructured":"Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, Simon LN (1973) Mechanism of action of 1\u2010 \u2010D\u2010ribofuranosyl\u20101,2,4\u2010triazole\u20103\u2010carboxamide (Virazole), a new broad\u2010spectrum antiviral agent. Proc Natl Acad Sci USA 70: 1174\u20131178","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM202013105_CR108","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41591-020-0868-6","volume":"26","author":"W Sungnak","year":"2020","unstructured":"Sungnak W, Huang N, B\u00e9cavin C, Berg M, Queen R, Litvinukova M, Talavera\u2010L\u00f3pez C, Maatz H, Reichart D, Sampaziotis F et al (2020) SARS\u2010CoV\u20102 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 26: 681\u2013687","journal-title":"Nat Med"},{"key":"BFEMMM202013105_CR109","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/v11040326","volume":"11","author":"EP Tchesnokov","year":"2019","unstructured":"Tchesnokov EP, Feng JY, Porter DP, Gotte M (2019) Mechanism of inhibition of ebola virus RNA\u2010dependent RNA Polymerase by Remdesivir. Viruses 11: 326","journal-title":"Viruses"},{"key":"BFEMMM202013105_CR110","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","volume":"20","author":"KK To","year":"2020","unstructured":"To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS et al (2020) Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS\u2010CoV\u20102: an observational cohort study. Lancet Infect Dis 20: 565\u2013574","journal-title":"Lancet Infect Dis"},{"key":"BFEMMM202013105_CR111","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3851\/IMP1410","volume":"14","author":"J van der Lugt","year":"2009","unstructured":"van der Lugt J, Lange J, Avihingsanon A, Ananworanich J, Sealoo S, Burger D, Gorowara M, Phanuphak P, Ruxrungtham K (2009) Plasma concentrations of generic lopinavir\/ritonavir in HIV type\u20101\u2010infected individuals. Antivir Ther 14: 1001\u20131004","journal-title":"Antivir Ther"},{"key":"BFEMMM202013105_CR112","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1128\/AAC.01156-16","volume":"60","author":"E Vanderlinden","year":"2016","unstructured":"Vanderlinden E, Vrancken B, Van Houdt J, Rajwanshi VK, Gillemot S, Andrei G, Lemey P, Naesens L (2016) Distinct effects of T\u2010705 (Favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob Agents Chemother 60: 6679\u20136691","journal-title":"Antimicrob Agents Chemother"},{"key":"BFEMMM202013105_CR113","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1128\/JVI.01382-16","volume":"90","author":"FS Varghese","year":"2016","unstructured":"Varghese FS, Thaa B, Amrun SN, Simarmata D, Rausalu K, Nyman TA, Merits A, McInerney GM, Ng LFP, Ahola T (2016) The antiviral alkaloid berberine reduces chikungunya virus\u2010induced mitogen\u2010activated protein kinase signaling. J Virol 90: 9743\u20139757","journal-title":"J Virol"},{"key":"BFEMMM202013105_CR114","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1021\/jp102619w","volume":"114","author":"J Villala\u00edn","year":"2010","unstructured":"Villala\u00edn J (2010) Membranotropic effects of arbidol, a broad anti\u2010viral molecule, on phospholipid model membranes. J Phys Chem B 114: 8544\u20138554","journal-title":"J Phys Chem B"},{"key":"BFEMMM202013105_CR115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","volume":"2","author":"MJ Vincent","year":"2005","unstructured":"Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2: 69","journal-title":"Virol J"},{"key":"BFEMMM202013105_CR116","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the SARS\u2010CoV\u20102 spike glycoprotein. Cell 181: 281\u2013292","journal-title":"Cell"},{"key":"BFEMMM202013105_CR117","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/cr.2008.15","volume":"18","author":"H Wang","year":"2008","unstructured":"Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C (2008) SARS coronavirus entry into host cells through a novel clathrin\u2010 and caveolae\u2010independent endocytic pathway. Cell Res 18: 290\u2013301","journal-title":"Cell Res"},{"key":"BFEMMM202013105_CR118","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020a) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019\u2010nCoV) in vitro. Cell Res 30: 269\u2013271","journal-title":"Cell Res"},{"key":"BFEMMM202013105_CR119","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","volume":"6","author":"X Wang","year":"2020","unstructured":"Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X (2020b) The anti\u2010influenza virus drug, arbidol is an efficient inhibitor of SARS\u2010CoV\u20102 in vitro. Cell Discov 6: 28","journal-title":"Cell Discov"},{"key":"BFEMMM202013105_CR120","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q et al (2020c) Remdesivir in adults with severe COVID\u201019: a randomised, double\u2010blind, placebo\u2010controlled, multicentre trial. Lancet 395: 1569\u20131578","journal-title":"Lancet"},{"key":"BFEMMM202013105_CR121","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC et al (2016) Therapeutic efficacy of the small molecule GS\u20105734 against Ebola virus in rhesus monkeys. Nature 531: 381\u2013385","journal-title":"Nature"},{"key":"BFEMMM202013105_CR122","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/322858","volume":"184","author":"TE Wellems","year":"2001","unstructured":"Wellems TE, Plowe CV (2001) Chloroquine\u2010resistant malaria. J Infect Dis 184: 770\u2013776","journal-title":"J Infect Dis"},{"key":"BFEMMM202013105_CR123","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","volume":"585","author":"BN Williamson","year":"2020","unstructured":"Williamson BN, Feldmann F, Schwarz B, Meade\u2010White K, Porter DP, Schulz J, van Doremalen N, Leighton I, Yinda CK, P\u00e9rez\u2010P\u00e9rez L et al (2020) Clinical benefit of remdesivir in rhesus macaques infected with SARS\u2010CoV\u20102. Nature 585: 273\u2013276","journal-title":"Nature"},{"key":"BFEMMM202013105_CR124","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","volume":"581","author":"R W\u00f6lfel","year":"2020","unstructured":"W\u00f6lfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, M\u00fcller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C et al (2020) Virological assessment of hospitalized patients with COVID\u20102019. Nature 581: 465\u2013469","journal-title":"Nature"},{"key":"BFEMMM202013105_CR125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/03009747809095649","volume":"7","author":"FA Wollheim","year":"1978","unstructured":"Wollheim FA, Hanson A, Laurell CB (1978) Chloroquine treatment in rheumatoid arthritis. Correlation of clinical response to plasma protein changes and chloroquine levels. Scand J Rheumatol 7: 171\u2013176","journal-title":"Scand J Rheumatol"},{"key":"BFEMMM202013105_CR126","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS (2020) Cryo\u2010EM structure of the 2019\u2010nCoV spike in the prefusion conformation. Science 367: 1260\u20131263","journal-title":"Science"},{"key":"BFEMMM202013105_CR127","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0166-3542(85)90012-9","volume":"5","author":"SK Wray","year":"1985","unstructured":"Wray SK, Gilbert BE, Noall MW, Knight V (1985) Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res 5: 29\u201337","journal-title":"Antiviral Res"},{"key":"BFEMMM202013105_CR128","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-020-0184-0","volume":"5","author":"S Xia","year":"2020","unstructured":"Xia S, Lan Q, Su S, Wang X, Xu W, Liu Z, Zhu Y, Wang Q, Lu L, Jiang S (2020a) The role of furin cleavage site in SARS\u2010CoV\u20102 spike protein\u2010mediated membrane fusion in the presence or absence of trypsin. Signal Transduct Target Ther 5: 92","journal-title":"Signal Transduct Target Ther"},{"key":"BFEMMM202013105_CR129","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","volume":"17","author":"S Xia","year":"2020","unstructured":"Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S et al (2020b) Fusion mechanism of 2019\u2010nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol 17: 765\u2013767","journal-title":"Cell Mol Immunol"},{"issue":"15","key":"BFEMMM202013105_CR130","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","volume":"71","author":"X Yao","year":"2020","unstructured":"Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C et al (2020) In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS\u2010CoV\u20102). Clin Infect Dis 71(15): 732\u2013739","journal-title":"Clin Infect Dis"},{"key":"BFEMMM202013105_CR131","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.antiviral.2018.11.016","volume":"162","author":"MK Yates","year":"2019","unstructured":"Yates MK, Seley\u2010Radtke KL (2019) The evolution of antiviral nucleoside analogues: A review for chemists and non\u2010chemists. Part II: Complex modifications to the nucleoside scaffold. Antiviral Res 162: 5\u201321","journal-title":"Antiviral Res"},{"key":"BFEMMM202013105_CR132","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S2468-1253(20)30057-1","volume":"5","author":"C Zhang","year":"2020","unstructured":"Zhang C, Shi L, Wang FS (2020a) Liver injury in COVID\u201019: management and challenges. Lancet Gastroenterol Hepatol 5: 428\u2013430","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"BFEMMM202013105_CR133","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R (2020b) Crystal structure of SARS\u2010CoV\u20102 main protease provides a basis for design of improved \u03b1\u2010ketoamide inhibitors. Science 368: 409\u2013412","journal-title":"Science"},{"key":"BFEMMM202013105_CR134","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijid.2020.05.030","volume":"96","author":"R Zhou","year":"2020","unstructured":"Zhou R, Li F, Chen F, Liu H, Zheng J, Lei C, Wu X (2020) Viral dynamics in asymptomatic patients with COVID\u201019. Int J Infect Dis 96: 288\u2013290","journal-title":"Int J Infect Dis"},{"key":"BFEMMM202013105_CR135","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382: 727\u2013733","journal-title":"N Engl J Med"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202013105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.15252\/emmm.202013105","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.15252\/emmm.202013105\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.15252\/emmm.202013105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202013105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:29:53Z","timestamp":1779085793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.15252\/emmm.202013105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,11]]}},"alternative-id":["BFEMMM202013105"],"URL":"https:\/\/doi.org\/10.15252\/emmm.202013105","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.J.M., A.S., S.J.T., and J.R. declare no potential conflicts of interest. G.F. has served as an advisor to Gilead Sciences and has conducted clinical research supported by Gilead Sciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"EMMM202013105"}}